Advances in Anemia Management: Changing Treatment Paradigms
ISN Academy. Hao C.
Apr 24, 2019; 272231
Topic: Chronic kidney disease
Chuan-Ming Hao
Chuan-Ming Hao
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Description
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
Given the central role of abnormal EPO and iron homeostasis, current treatment paradigms center on the replacement of these in the form of various ESAs and iron (oral or IV in CKD, and mostly IV in ESRD). This paradigm has numerous flaws. ESA administration results in massively increased levels of circulating EPO, and while effective in raising Hgb concentrations in 90% of individuals, clinical trials examining its long-term outcomes have indicated negative effects when targeting normalization of blood hemoglobin levels. Combined with their high cost, this has resulted in a much more conservative approach, with significantly lower target hemoglobin levels, and with an increase in iron utilization. The long-term effects of the increased usage of iron (especially IV iron) remain unknown, but there are concerns about potential adverse effects. HIF-PHIs are a novel class of therapeutics which are in clinical development for the treatment of anemia in CKD and in ESRD. Studies suggests that HIF-PHIs increase endogenous EPO production to appropriate physiologic levels, like those seen after blood loss or in high-altitude acclimation and normalize iron homeostasis by decreasing functional iron deficiency. Phase 2 and 3 clinical trials have shown that HIF-PHIs are effective and safe treatments of anemia in patients with CKD and ESRD.
Expected Learning Outcomes:
Following are learning outcomes expected from the audience at the conclusion of this symposium.
  • Emphasis will be placed on these learning objectives and changes in practice. Examine the prevalence of and risk factors for hyperkalemia and its associated prognosis across healthcare settings
  • Appraise the recent shifts in treatment patterns that have occurred in the management of anemia in CKD
  • Describe commonly applied therapies for anemia and hyperkalemia and understand their advantages and disadvantages.
  • Become familiar with novel treatments for hyperkalemia and anemia, and their role in changing therapeutic paradigms optimizing management.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings